




# Neurobiologia dell'Autismo e cenni di epidemiologia

---




**Maria Luisa Scattoni, Ph.D.**

*Neurotoxicology and Neuroendocrinology Section  
Istituto Superiore di Sanità, Rome, Italy*

# nature


THE INTERNATIONAL WEEKLY JOURNAL OF SCIENCE



Sorting fact  
from fiction in  
the debate over  
autism spectrum  
disorder **PAGE 21**

## THE AUTISM ENIGMA

Special Issue November 2011



***“I bambini del  
nostro gruppo hanno  
manifestato la loro profonda  
solitudine dall’inizio della loro  
vita, non rispondendo a niente  
che provenisse dal  
mondo esterno”***

*Leo Kanner,  
Johns Hopkins University  
Autistic disturbances of affective contact  
Nervous Child 2:217-250, 1943*



# Un pò di storia...

---

1943: Leo Kanner

1952: Early-onset schizophrenia

1980: Infantile autism


1987: Autism Disorder

2000: Autism Spectrum Disorders: autism disorder, Asperger's syndrome, Rett Syndrome and pervasive developmental disorder not otherwise specified' (PDD-NOS)

# Epidemiologia

## Diagnosis: rising

By some counts, autism diagnoses have climbed steadily since the 1970s. Some research has found explanation for more than half of the rise (right).



## CDC:

More than 90 in 10000 eight-year-olds in the United States had autism



# Epidemiologia

---

*“Current US prevalence for autism is low because they don’t look at the entire population. Many US studies are based on diagnosed cases of autism”,*

*Grinker, 2001*

## **SOUTH KOREA: 1 in 38**

In the 1980s, he had found Korean families generally unwilling to admit that anything might be wrong with their children, because of the stigma attached. But when he undertook the latest study, attitudes had changed. Families in Ilsan, a stable, residential community on the outskirts of Seoul, welcomed information about autism, which in this study was offered confidentially.

His team screened more than **55,000 children born between 1993 and 1999**, and came up with an estimated prevalence for ASD of 1 in 38.





# Epidemiologia

---

## Alcuni studi evidenziano come la prevalenza è sempre stata alta

1) Terry Brugha, a psychiatrist at the University of Leicester, UK

His team knocked on more than 7,000 doors across England: he calculated a prevalence of autism in adults of **9.8 in 1,000** — close to the frequency found in US children.

Brugha, T. S. *et al.* *Arch. Gen. Psychiatry* **68**, 459–465 (2011).

2) Christopher Gillberg, child and adolescent psychiatry at the University of Gothenburg in Sweden

He found a prevalence of autism of **0.7%** among seven-year-old Swedish children in 1983 and **1%** in 1999.

Gillberg, C. J. *Child Psychol. Psychiatry* **24**, 377–403 (1983).

Kadesjö, B., Gillberg, C. & Hagberg, B. J. *Autism Dev. Disord.* **29**, 327–331 (1999).



# Epidemiologia

---

Peter Bearman, a sociologist at Columbia University in New York:


He analyzed nearly 5 million California birth records and 20,000 records from the state's department of developmental services

By linking **birth** with **detailed diagnostic data** he was able to generate a rich picture of the demographics and life history of those with autism, which yielded clues to the social factors that influence diagnosis.



# Epidemiologia

## Reasons: unclear



**He still cannot explain 46% of the increase in autism:  
new environmental pollutants?**



# Environment?

---

**During the past decade:**

- **the US federal government has spent about:**

- **\$1 billion researching the genetics of autism**

- **\$40 million on studies of possible environmental factors**

## Autism Spectrum Disorders (ASDs)

### ASDs Homepage

Facts

Screening & Diagnosis

Treatment

Related Topics

Data & Statistics

Research

ADDM

CADDRE

▶ SEED

Frequently Asked Questions

Georgia SEED

What to Expect

How to Prepare

[National Center Homepage](#) > [ASDs Homepage](#) > [Research](#)

## Study to Explore Early Development (SEED)

The Study to Explore Early Development (SEED) is a multi-year study funded by CDC. It is currently the largest study in the United States to help identify factors that may put children at risk for autism spectrum disorders (ASDs) and other developmental disabilities. Understanding the risk factors that make a person more likely to develop an ASD will help us learn more about the causes.




[What is SEED?](#)

**Under the auspices of CDC,** began recruiting about 2700 children aged two to five

The study includes developmental evaluations, questionnaires, a review of medical records and analysis of blood, cheek-cell and hair-samples to examine genetic make-up exposures to environmental chemicals

# SEED

The six SEED study sites and a data coordinating center are part of the Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE) network.





# EARLI

The screenshot shows the top portion of the EARLI website. At the top right, there are language options for "English" and "Español". Below this, the EARLI logo is displayed in teal, followed by the text "Early Autism Risk Longitudinal Investigation" and "Finding Clues About Autism with Growing Families". To the right of the logo, there is a "Current Study Participants" section with a lock icon and a "Login »" link, and a search bar with a magnifying glass icon. A navigation menu below the header includes "Home", "Participation", "Research Sites", "About the Study", "Investigators", "FAQs", and "Contact Us". The main banner features a photograph of three children and the text "How do genes and environmental factors interact to cause autism?". On the right side of the banner, there are three buttons: "Download the Study Brochure", "Join Our Mailing List", and "Find Out How to Enroll", each with a right-pointing arrow icon.

**Funded by NIH** is enrolling up to 1200 families that have a child with autism and are preparing to have another baby

The study intends to look for any interplay between environmental factors and genetic susceptibility that might contribute to autism risk in their next child

# Geni e ambiente

**COMPONENTE  
AMBIENTALE**

**DISTURBI DELLO  
SPETTRO  
AUTISTICO**

**COMPONENTE  
GENETICA**

## **ESPOSIZIONE IN UTERO A:**

- **Virus della rosolia**
- **Elevati livelli di testosterone**
- **Sostanze che causano difetti alla nascita: alcool etilico, acido valproico** (farmaco antiepilettico), **talidomide** (farmaco tranquillante ed antiematico)
- **Sono in studio gli organofosfati** (sostanze comunemente usate come pesticidi in agricoltura e come insetticidi in ambito domestico)


## **MICROARRAY**



**Copy number variations (CNVs)**  
(Delezione o duplicazione di piccoli segmenti di DNA)

**Mutazioni puntiformi (SNPs)**  
(Polimorfismo di un singolo nucleotide)

# Sintomi (DSM-IV)







# Causes of Autism Spectrum Disorders: strongest evidence is genetic

---

- 4:1 frequency ratio boys:girls in ASD (8:1 in AS e 1:1 quando  $QI < 50$ )
- Concordance is 60-80% for monozygotic twins
- Concordance is 20-30% in dizygotic twins
- Linkage analyses indicate many genes underlying Autism Spectrum Disorders, including linkages at chromosomal loci 15q11-q13, 16p11.2, 22q13, X-linked
- Multiple putative candidate genes include *GABA-β3*, *5-HTT*, *MET*, *PTEN*, *En2*, *UBE3a*, *CNTNAP2*, neurexins, neuroligins, shanks, SYN-1 and genes for comorbid neurodevelopmental disorders including *FMR1*, *MECP2*, *TSC*



# High risk infants

---

## PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

**Recurrence Risk for Autism Spectrum Disorders: A Baby Siblings Research Consortium Study**

Sally Ozonoff, Gregory S. Young, Alice Carter, Daniel Messinger, Nurit Yirmiya, Lonnie Zwaigenbaum, Susan Bryson, Leslie J. Carver, John N. Constantino, Karen Dobkins, Ted Hutman, Jana M. Iverson, Rebecca Landa, Sally J. Rogers, Marian Sigman and Wendy L. Stone

*Pediatrics*; originally published online August 15, 2011;  
DOI: 10.1542/peds.2010-2825



# **Baby Siblings Research Consortium Study**


---

**finanziato da AUTISM SPEAKS**

- **12 siti negli Stati Uniti**
- **664 bambini ad alto rischio reclutati e seguiti fino ai 36 mesi**
- **132 bambini diagnosticati con DSA (41% autismo; 59% con Disturbi generalizzati dello sviluppo non altrimenti specificati)**

**RISCHIO SALITO AL 18% (25.9% nei maschi e 9.6% nelle femmine)**

# La complessità della genetica alla base dei DSA



- ASD candidates
- Genes showing association with ASD
- ASD genes

# SnapShot: Genetics of Autism

Neuron

Kimberly A. Aldinger, Jasmine T. Plummer, Shenfeng Qiu, and Pat Levitt  
Keck School of Medicine of USC, Los Angeles, CA, 90089, USA

|                      | CHR           | GENE   | PROTEIN FUNCTION  | HUMAN PHENOTYPE (MUTANT MOUSE PHENOTYPES)   |
|----------------------|---------------|--|---|---|
| Mendelian Syndromes* | 6q23.3        | (AP11*)  | Joubertin; interacts with $\beta$ -catenin in cilia   | Joubert syndrome. (Reduced brain and body size. Cerebellar, retinal, and kidney defects. Most die by P10. Neuron-specific loss leads to depressive-like phenotypes.)  |
|                      | 7q35-q36.1    | (CNTNAP2*)   | Caspr2, a neuresin family member; clusters voltage-gated K <sup>+</sup> channels  | Recessive EPI syndrome, ASD, ADHD, TS, OCD. (Neuronal migration defects. Reduced GABAergic neurons and decreased cortical synchrony. Seizures. Deficits in social, repetitive behaviors, and USV.)  |
|                      | 9q34.13       | (TSC1)   | Hamartin, a growth inhibitory protein that negatively regulates the mTOR pathway  | Tuberous Sclerosis type I. (Liver and neural tube defects. Die by E12. Abnormal kidney and liver growth in heterozygotes. Variable brain structure, function and behavior abnormalities in conditional mutants. Die at various postnatal ages. Neuron-specific loss causes abnormal spine morphology and cortical excitability. Loss of LTD.) |
|                      | 10q23.31      | (PTEN)   | Protein tyrosine phosphatase; negatively regulates the mTOR pathway   | Cowden disease. (Placenta and germ cell defects. Die by E9.5. Neuron-specific loss alters synaptic physiology. Heterozygotes have prostate, skin and colon defects, and spontaneous tumors. Macrocephaly, neuronal hypertrophy, abnormal social interaction, and increased survival in conditional mutants.)                                  |
|                      | 11q13.4       | (DHCRT)  | Final enzyme in cholesterol biosynthetic pathway  | Smith-Lemli-Opitz syndrome. (Craniofacial and lung abnormalities. Die by P1. Abnormal cholesterol regulation and enlarged bladders. Hypomorphic mutants are viable and fertile. Compound mutants have fused toes, enlarged ventricles, and 25% embryonic lethality.)  |
|                      | 12p13.33      | (CACNA1C)  | $\alpha$ -1 subunit of a voltage-dependent Ca <sup>2+</sup> channel   | Timothy syndrome. (Die embryonically. Impaired pancreatic function. Motor defects and antidepressant-like behavior in heterozygotes; anxiety-like deficits in females. Neuron-specific loss, impaired cognition and LTP.)   |
|                      | 15q11.2       | (UBE3A)  | Ubiquitination ligase; targets protein degradation system   | Angelman syndrome. (Small brain, seizure susceptibility, motor and learning deficits. Reduced spine density and impaired LTP. Impaired synapse maturation and plasticity.)  |
|                      | 16p13.3       | (TSC2)   | Tuberin; which negatively regulates the mTOR pathway  | Tuberous Sclerosis type II. (Heart, neural tube, and motor defects. Purkinje cell death. Die by E12. Various tumors and axon guidance defects in heterozygotes. Dominant-negative mutant has enhanced anxiety-like behaviors; motor, learning, social behavior deficits.)   |
|                      | 17q11.2       | (NF1)  | Neurofibromin; a GTPase activator and negative regulator of RAS signaling   | Neurofibromatosis. (Macrocephaly, small eyes, and heart defects. Delayed organ development. Embryonic lethal. Increased astrocytes and tumor susceptibility. LTP and learning and memory deficits in heterozygotes.)  |
|                      | Xp21.2        | (DMD)  | Dystrophin; cytoskeletal protein bridging ECM   | Duchenne muscular dystrophy. (Muscle and heart defects in hemizygous males and homozygous females. Reduced fertility. Abnormal retinal electrophysiology and synapse organization, density, and maturation.)  |
|                      | Xp21.3        | (ARX)  | Aristaless-related homeobox protein TF  | LIS, XLID, EPI, ASD. (Hemizygous males die perinatally. Decreased inhibitory synaptic transmission. Males hemizygous for point mutations or triple repeat expansions have seizures. Deficits in behavior and GABAergic neuron generation and migration.)  |
|                      | Xq27.3        | (FMR1)   | Fragile X mental retardation protein; an RNA-binding protein that traffics mRNA   | Fragile X syndrome. (Seizures. Enlarged testes in males. Learning and social behavior deficits. Dendritic spine abnormalities. Enhanced LTD and impaired LTP. Altered cortical drive and E/I neuronal cortical networks.)   |
|                      | Xq28          | (MECP2)  | MeCP2; involved in transcriptional regulation and chromatin organization  | Rett syndrome. (Brain, breathing, and motor defects in hemizygous males. Mild cognitive and anxiety-like phenotypes in heterozygous females. Various conditional loss and postnatal reduction mimic null phenotypes in adult hemizygous males. Impaired excitatory synapses and spine morphology. Increased neuronal connectivity.)           |
|                      | Rare Variants | 2p16.3   | (NRXN1)   | A neuresin; forms intracellular junctions through neuroligin binding  |
| 3p13                 |               | (FOXP1)  | A forkhead box TF   | ID, ASD, SLL. (Cardiovascular defects. Die embryonically.)  |
| 6q16.3               |               | (GRK2*)  | A postsynaptic glutamate receptor subunit   | Recessive ID. (Increased sensitivity to drug-induced seizures. Elevated startle and pain threshold. Impaired synaptic plasticity and inhibitory transmission.)  |
| 7q31.1               |               | (FOXP2)  | A forkhead box TF   | SLL. (Growth retardation, reduced USV, cerebellar, motor and neurological defects. Perinatal death. Impaired LTD and plasticity.)   |
| 15q11-q13            |               |  |   | ASD, EPI, ID. (Cleft palate in deletion mutants; die by P3; motor, and cognitive deficits. Seizures. Increased newborn USV in maternal heterozygotes. Reduced activity, social interactions, and USV. Increased anxiety-like behavior in duplications.)   |
| 16p11.2              |               |  |   | ASD, ADHD, ID, EPI, SCZ. (Mild structural brain defects and gene dose-dependent behavioral phenotypes.)   |
| 17q11.2              |               | (SLC6A4)   | 5-HT transporter  | ASD, OCD. (Heart defects. Hyperactive, aggressive, anxiety-like behaviors, and learning deficits.)  |
| 22q11.21             |               |  |   | DiGeorge syndrome, SCZ, ASD, ID. (Sensorimotor, learning, and memory deficits. Hyperactivity. Increased anxiety-like behavior.)   |
| 22q13.33             |               | (SHANK3)   | A PSD scaffold protein  | ASD. (Variable phenotypes including excessive grooming, anxiety-like behavior, and disrupted social interactions. Abnormal dendritic spines. Reduced synaptic transmission, LTP, LTD, and NMDAR-dependent responses.)   |
| Xq22.32-p22.31       |               | (NLGN4X)   | A neuroligin; ligand for $\beta$ -neuroligins   | ASD, ID, TS, ADHD. (Reduced brain size. Social interaction and USV deficits.)   |
| Xq13.1               | (NLGN3*)      | A neuroligin; ligand for $\beta$ -neuroligins              | ASD. (Reduced brain size. Abnormal learning, social behavior, USV, and olfaction. Hyperactivity, altered E/I balance shift caused by increased inhibitory synaptic transmission.)             |   |
| Common Alleles       | 1q42.2        | (DISC1)  | Large transmembrane protein involved in neurite outgrowth and brain development   | (Region-specific changes in neuronal morphology. Homozygote and heterozygote learning and memory deficits. Reduced neurogenesis and altered neuron distribution. Abnormal dendritic spines. Reduced short-term plasticity.)   |
|                      | 2q31.1        | (SLC25A12)   | Mitochondrial Ca <sup>2+</sup> -binding carrier   | (Growth retardation. Tremors, myelination and motor defects. Die E18-P15.)  |
|                      | 3p25.3        | (OXTR)   | GPCR for oxytocin   | (Abnormal maternal behavior. Hypoactivity, increased aggression and USV in males. Social memory deficits. Fewer GABAergic synapses.)  |
|                      | 7q31.2        | (MET)  | Receptor tyrosine kinase  | (Muscle, axon guidance, placenta, and liver defects. Die by E14. Abnormal cortical dendrites/spines and hyperconnectivity of local circuits in conditional mutant.)   |
|                      | 7q22.1        | (RELN)   | Large secreted ECM protein involved in cell-cell interactions   | (Reduced body size and premature death in some mutants. Retinal, olfactory, and fertility defects. Various neuron structural, functional, and localization abnormalities. Impaired PPI and LTP and reduced inhibitory tone in heterozygotes.)   |
|                      | 7q36.3        | (EN2)  | Homeobox TF critical for hindbrain patterning   | (Deficits in cerebellar development. Altered DA neuron generation and degeneration. Hyperactivity. Motor, learning, and grooming impairments.)  |
|                      | 12q14.2       | (AVPR1A)   | GPCR for arginine vasopressin   | (Impaired spatial memory and reduced PPI. Social deficits in females. Reduced anxiety-like behaviors in males.)   |
| 17q21.32             | (ITGB3)       | Mediates platelet cell adhesion and cell-surface signaling | (Platelet defects, anemia, internal bleeding, increased bone mass, hypocalcemia, and premature death. 50% die embryonically from placental defects. Altered social and repetitive behaviors.) |   |

## Mendelian Syndromes

12p13.33 (CACNA1C) Timothy Syndrome  
15q11.2 (UBE3A) Angelman Syndrome  
Xq27.3 (FMR1) Fragile X Syndrome  
Xq28 (MECP2) Rett Syndrome

## increase in risk for ASDs

## Rare variants

2p16.3 (NRXN1) ASD, ID, language delay, SCZ  
3p13 (FOXP1) ID, ASD  
22q13.33 (SHANK3) ASD  
Xp22.32-p22.31 (NLGN4X) ASD, ID, TS, ADHD  
Xq13.1 (NLGN3) ASD

## Common Alleles

1q42.2 (DISC1)  
7q22.1 (RELN)  
7q36.3 (EN2)



# SnapShot: Autism and the Synapse

João Peça,<sup>1</sup> Jonathan Ting,<sup>1</sup> and Guoping Feng<sup>1</sup>



<sup>1</sup>McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Cell


706 Cell 147, October 28, 2011 ©2011 Elsevier Inc. DOI 10.1016/j.cell.2011.10.015

See online version for legend and references.

| Gene/Protein                                      | Locus | Evidence                                 |
|---|-------|--|
| PROSAP2/<br>Shank3<br>Phelan-McDermid<br>syndrome | 22q13 | Schizophrenia                            |
| PROSAP1/<br>Shank2                                | 11q13 | Schizophrenia                            |
| DLG1/SAP97<br>3q29 deletion<br>syndrome           | 3q29  | Autism and schizophrenia + Schizophrenia |
| DLG4/<br>PSD95                                    | 17p13 | Schizophrenia                            |
| DLGAP2/<br>SAPAP2                                 | 8p23  | Schizophrenia                            |
| DLGAP3/<br>SAPAP3                                 | 1p34  | OC-Spectrum disorders                    |
| GRIK2/<br>GurR8                                   | 6q16  | Intellectual disability                  |
| NRXN1/<br>Neurexin1                               | 2p16  | Schizophrenia                            |
| NRXN2/<br>Neurexin2                               | 11q13 | Schizophrenia                            |
| NLGN1/<br>Neuroigin1                              | 3q26  | Schizophrenia                            |
| NLGN3/<br>Neuroigin3                              | Xq13  | Schizophrenia                            |
| NLGN4/<br>Neuroigin4                              | Xp22  | Schizophrenia                            |
| TSC1/hamartin<br>tuberous sclerosis<br>complex    | 9q34  | Schizophrenia                            |
| TSC2/tuberin<br>tuberous sclerosis<br>complex     | 16p13 | Schizophrenia                            |
| FMR1/FMRP<br>fragile X syndrome                   | Xq27  | Schizophrenia                            |
| UBE3A/E6AP<br>Angelman syndrome                   | 15q11 | Schizophrenia                            |










# Geni della funzionalità sinaptica






# Analisi dei trascritti (trascrittomica)




| Gene ontology category              | p-value  |
|-------------------------------------|----------|
| <i>Down-regulated genes (N=209)</i> |          |
| Synapse                             | 4.48E-08 |
| Axon                                | 5.07E-07 |
| Neuropeptide hormone activity       | 2.62E-06 |
| Synaptic transmission               | 9.96E-07 |
| Synaptic vesicle                    | 2.98E-04 |
| <i>Up-regulated genes (N=235)</i>   |          |
| Immune response                     | 5.59E-09 |
| Regulation of cell proliferation    | 6.96E-08 |
| Cell adhesion                       | 3.34E-06 |
| Negative regulation of cell death   | 6.86E-06 |
| Inflammatory response               | 7.73E-06 |
| Immunoglobulin domain               | 4.12E-04 |


# Dendritic spine pathology in neuropsychiatric disorders



# Dendritic spine pathology in ASD




# Neuroni e spine dendritiche




**Neurone di controllo:**  
proteine in equilibrio derivate da un  
corretto livello di espressione

**Sindrome dell' X fragile:**  
normal dendrites but an  
increased density of  
longer, thinner, immature-  
appearing dendritic spines



**Sindrome di Angelman:**  
normal dendrites but a decreased  
density of, and abnormally  
shaped, dendritic spines





**Sindrome di Rett :**  
(Mecp2-null mice)  
decreased density of dendrites  
and decreased density of,  
and abnormally shaped, synapses  
(represented by dendritic spines)

**Sindrome di Rett :**  
(Mecp2 is duplicated)  
increased density of synapses  
(represented by increased density of  
dendrites and dendritic spines)

# Variazioni anche nel numero di neuroni

**Il peso del cervello è maggiore nei bambini autistici**

Corteccia prefrontale:




n = 7      n = 6  
tra i 2 e i 16 anni




# Variazioni anche nel numero di neuroni

Nella corteccia prefrontale si osserva un maggior numero di neuroni



Le cause dell'aumento di neuroni sono da ricercare al livello prenatale

# Problemi di connettività





# Problemi di connettività

Characterization of functional connectivity with rs-fcMRI

Mouse models  
of NDDs



Manipulate specific  
neuronal activity


Inhibit

Disrupt functional  
connectivity?

Drive

Enhance functional  
connectivity?


# Squilibrio eccitazione-inibizione



# SnapShot: Neuroligin-Neurexin Complexes

# Cell

Stéphane Baudouin and Peter Scheiffele  
Biozentrum of the University of Basel, 4056 Basel, Switzerland




# GABA

- in the **mature brain** GABA acts as an inhibitory transmitter
- during the **embryonic** and the **perinatal period**, this neurotransmitter depolarizes targeted cells and triggers calcium influx

**REGOLA** molti processi durante lo sviluppo:

- Proliferazione cellulare
- Migrazione
- Differenziamento
- Maturazione sinaptica
- Morte cellulare






| Mouse model                             | Alterations in GABAergic signaling   |
|---|--|
| <i>Mecp2</i> -KO<br>(Rett syndrome)     | <p>Reduced levels of GAD65 and GAD67 (<i>Viaat-Mecp2<sup>-/-</sup></i>)</p> <p>Reduced inhibitory quantal size in layer 2/3 pyramidal neurons of the somatosensory cortex</p> <p>The E/I balance is shifted to favor inhibition over excitation in cortical networks (<i>Mecp2<sup>2lox/x</sup>, Nestin-Cre</i>)</p> <p>Reduced frequency of IPSC-based spontaneous rhythmic field potentials in the hippocampus (<i>Mecp2<sup>tm1.1Bird</sup></i>)</p>                                  |
| <i>Fmr1</i> -KO<br>( <i>X fragile</i> ) | <p>Down regulation of GABAA-mediated tonic inhibition in the subiculum</p> <p>Reduced expression of <math>\alpha 5</math> and <math>\delta</math> GABAA receptor subunits in the subiculum</p> <p>Increased frequency of sIPSCs and mIPSCs in the striatum</p> <p>Reduction in amplitude and frequency of sIPSCs and mIPSCs</p> <p>Reduced GABAA-mediated tonic inhibition</p> <p>Reduced GABAergic innervation in the amygdala</p> <p>Reduced expression of GABAA receptor subunits</p> |
| <i>Gabrb3</i> KO                        | The E/I balance is shifted to favor excitation over inhibition in cortical networks (EEG recordings)   |
| <i>Dlx1/Dlx2</i> KO                     | <p>Abnormal cell migration</p> <p>Reduction in the number of GABAergic interneurons in the cortex, olfactory bulb and hippocampus</p>  |
| <i>Reln</i> -KO                         | <p>Reduced level of GAD67</p> <p>Decreased GABA turnover</p>   |
| <i>En2</i> -KO                          | <p>Reduced expression of parvalbumin- and somatostatin-positive GABAergic interneurons in the hippocampus</p> <p>Increased susceptibility to seizures</p>  |
| <i>Nlg3</i> R451C KI                    | <p>Increased frequency of mIPSC</p> <p>Increased level of VGAT and gephyrin</p> <p>Asymmetric reduction of PV positive basket cells across cortical hemispheres</p>  |
| valproic acid                           | <p>The E/I balance is shifted to favor excitation over inhibition in the lateral amygdala (multi electrode arrays)</p> <p>Asymmetric reduction of PV positive basket cells across cortical hemispheres</p>   |

# X-fragile

*Fmr1* (*fragile X mental retardation 1*): sul braccio lungo del cromosoma X (Xq27.3) codifica per la proteina FMRP

- mental retardation with language deficits,
- hyperactivity,
- autistic behavior
- seizures



## the 'mGluR theory of fragile X'

In assenza di FMRP:

- attivazione recettori mGluR5 (recettori metabotropici del glutammato) conduce ad un'eccessiva sintesi di proteine sinaptiche
- impairment of GABAergic circuitry and a decreased expression of GABAA receptor subunits

Loss of GABAergic function = hyper excitability

# Nonostante tutte queste osservazioni non esistono dei marcatori precoci per l'autismo perchè:


- Il disturbo si sviluppa tra il periodo pre-natale e la prima adolescenza quindi si possono sviluppare interazioni tra fattori di rischio multipli
- I pochi biomarcatori candidati non sono stati rilevati in tutti i pazienti autistici
- Biomarcatori trovati sono spesso associati con altri disturbi del neurosviluppo

| Biomarker type           | Sample/measure                           |
|--------------------------|--|
| Gene expression profile  | Blood samples                            |
| Proteomic profile        | Serum samples                            |
| Metabolomic profile      | Urine samples                            |
| Head size                | Head circumference trajectory            |
| Brain size and structure | MRI, DTI                                 |
| Brain function           | Functional MRI, EEG, ERPs                |
| Eye movement             | Looking measures, saccadic reaction time |

DTI, diffusion tensor imaging; EEG, electroencephalography; ERPs, event-related potentials.




# Crescita cerebrale anomala:



**Circonferenza cranica:**  
valore medio  
normale


# Quali sono le aree cerebrali coinvolte nell'autismo?



| Social impairment   | Communication deficits   | Repetitive behaviors   |
|---|--|--|
| OFC – Orbitofrontal cortex<br>ACC – Anterior cingulate cortex<br>FG – Fusiform gyrus<br>STS – Superior temporal sulcus<br>A – Amygdala mirror neuron regions<br>IFG – Inferior frontal gyrus<br>PPC – Posterior parietal cortex | IFG- Inferior frontal gyrus (Broca's area)<br>STS – Superior temporal sulcus<br>SMA – Supplementary motor area<br>BG – Basal ganglia<br>SN – Substantia nigra<br>Th – Thalamus<br>PN – Pontine nuclei cerebellum | OFC – Orbitofrontal cortex<br>ACC – Anterior cingulate cortex<br>BG – Basal ganglia<br>Th – Thalamus |

# ISS and NIMH STRATEGY

for testing genetic hypotheses about the causes of autism



# Mouse Models with Mutations in Candidate Genes

*Adapted from Abrahams and Geschwind, Nature Reviews Genetics 2008*

| Human Gene        | Co-morbid Syndrome             | Mutant Mouse |
|-------------------|--------------------------------|--------------|
| <i>AVPR1a</i>     |                                | Yes          |
| <i>CACNA1C</i>    | Timothy                        | Yes          |
| <i>CADPS2</i>     |                                | No           |
| <i>CNTNAP2</i>    |                                | Yes          |
| <i>DHCR7</i>      | Smith-Lemli-Opitz              | Yes          |
| <i>EN2</i>        |                                | Yes          |
| <i>FMR1</i>       | Fragile X                      | Yes          |
| <i>GABARβ2</i>    |                                | Yes          |
| <i>ITBG3</i>      |                                | Yes          |
| <i>MECP2</i>      | Rett                           | Yes          |
| <i>MET</i>        | (tumors)                       | Yes          |
| <i>NRXN1</i>      |                                | Yes          |
| <i>NLGN3</i>      |                                | Yes          |
| <i>NLGN4</i>      |                                | Yes          |
| <i>OXTR</i>       |                                | Yes          |
| <i>PTEN</i>       | (cancers)                      | Yes          |
| <i>RELN</i>       |                                | Yes          |
| <i>SHANK3</i>     | 22q13 deletion Phelan-McDermid | Yes          |
| <i>SLC6A4</i>     |                                | Yes          |
| <i>TSC1, TSc2</i> | Tuberous sclerosis             | Yes          |
| <i>UBE3A</i>      | Angelman                       | Yes          |



# Why are Mouse Models Useful?

---

**Mice and humans share 99% of their genes**

**Similar brain anatomy**

**Similar biochemistry, neurotransmitters, receptors**




**Similar physiology, brain electrophysiology**

**Analogous behavioral endophenotypes**

***Mice are a social species***




# Some social behaviors of *Mus musculus*




Nesting pattern of wild type(+/+) and *Dvl 1* mutant mice

+/+



-/-





# La famiglia dei geni SHANK

---



RESEARCH

Open Access

Haploinsufficiency of the autism-associated *Shank3* gene leads to deficits in synaptic function, social interaction, and social communication

ARTICLE

doi:10.1038/nature09965

***Shank3* mutant mice display autistic-like behaviours and striatal dysfunction**

João Peça<sup>1,2\*</sup>, Cátia Feliciano<sup>1,3\*</sup>, Jonathan T. Ting<sup>1</sup>, Wenting Wang<sup>1</sup>, Michael F. Wells<sup>1</sup>, Talignair N. Venkatraman<sup>4</sup>, Christopher D. Lascola<sup>1,4</sup>, Zhanyan Fu<sup>1,5,6</sup> & Guoping Feng<sup>1,6,7</sup>


**Autism is a  
neurodevelopmental disorder  
that is behaviorally defined  
by three core symptoms:**

# Animal Models of Autism


## Core Symptom #1

### Sociability Deficit


Abnormal reciprocal social interactions, with deficits in eye gaze, joint attention, empathy



# Sociability in Adult C57BL/6J (B6) Mice






**“Normal”  
mouse**



**“Autistic”  
mouse**





## Core Symptom #2

# Impairment in Social Communication

delayed onset and lower frequency of babbling, grunting, extended humming, stereotypic squeals, or laughing inappropriately



**Mice communicate primarily with ultrasonic vocalizations**

# Proposed DSM-5 criteria:

---



two symptom criteria sets:

- 1) social communication and interaction
- 2) restricted, repetitive behavior



# Adult Ultrasonic Vocalizations

C57BL/6J male mouse



# B6 male-female social interactions

---






# BTBR male-female social interactions

---





# Sociability deficit



## **Core Symptom #3**




# **Stereotyped Repetitive Behaviors and Narrow Restricted Interests**

**Videoscoring of spontaneous stereotyped  
jumping, grooming**



**Perseveration as a failure to make a change in a  
search strategy, using Morris water maze and  
T-maze spatial tasks**

**Restricted interests in a holeboard exploration  
task**

# Self-Grooming



# Densità sinaptica





# SHANK3

---

Incorporate behavioral phenotypes for all 3 symptoms of autism

- Reduced sociability (social approach)
- Repetitive behaviors (greater self-grooming)
- Communication deficits (low number of ultrasonic vocalizations during male-female interaction)



# Modelli animali transgenici:

---

- Valutare la complessa **interazione gene-ambiente**
- Studiare i **pathways neurobiologici** alla base dei tre sintomi principali dell'autismo
- Esplorare eventuali **interventi terapeutici/comportamentali**



# Conclusioni

---

L'autismo è contraddistinto da una grande eterogeneità che rende difficoltosa la validazione di teorie eziopatologiche capaci di sintetizzare gli aspetti cognitivi, comportamentali e fisiologici.

Approssimativamente 67 milioni di persone nel mondo sono affette da autismo, più di quante ne colpiscono i tumori, il diabete e l'AIDS messi insieme.


Non esiste una cura per l'autismo ma la diagnosi e un intervento precoce ne migliorano l'esito



**la figura del PEDIATRA è indispensabile**

# Grazie per l'attenzione

---



*“Non-invasive tools for early detection of  
Autism Spectrum Disorders”*

Ministero della Salute- Progetto Giovani Ricercatori 2008